NASDAQ:SOPH

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...

2022-01-11 20:27 1772

Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business

BOSTON and LAUSANNE, Switzerland, Jan. 10, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the hiring of Peter Casasanto as Chief B...

2022-01-10 20:28 2171

SOPHiA GENETICS Announces Launch of DEEP-Lung-IV Multimodal Clinical Study

Study to leverage deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Large-scale, multicentric real-world study aims to enro...

2021-12-02 02:30 1937

SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021

Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare alliance to provide joint solutions and multimodal analytics to healthcare providers and biopharma...

2021-11-30 03:35 2280

SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8

New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven ...

2021-11-01 20:03 1918

SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases

SOPHiA Clinical Exome Solution v3 offers a streamlined end-to-end workflow to facilitate the assessment of challenging Mendelian disorders BOSTON and LAUSANNE, Switzerland, Oct. 13, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing...

2021-10-13 05:16 1798
12

Week's Top Stories